Otonomy, Inc. Logo
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
June 11, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
June 10, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy to Host Pipeline Program Update Conference Call and Webcast
June 08, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
May 12, 2020 08:00 ET | Otonomy, Inc.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy, Inc. Logo
Otonomy Provides Business Update Related to COVID-19 Pandemic
April 09, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
Otonomy, Inc. Logo
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 27, 2020 16:15 ET | Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30...
Otonomy, Inc. Logo
Otonomy to Present at Two Upcoming Investor Conferences
February 24, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
February 20, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
January 28, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...